IP Library Granted Patent US 8,486,895
Granted Patent B2
US 8,486,895 · App. 13/509,237 · Granted Jul 16, 2013

Anti-epidermal growth factor receptor antibodies and uses thereof

Inventors: David Weaver (Beijing, CN); Michael Rynkiewicz (Beijing, CN); Cheng Cao (Beijing, CN); Yanwen Jin (Beijing, CN)
Assignee: Guangzhou Yunyuan Biotech Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,486,895
App. No.
13/509,237
Granted
Jul 16, 2013
Kind
B2
Abstract

The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 5.09×10 −10 mol/L) and are able to inhibit the growth and migration of tumor cells. The present invention also discloses the preparation methods and uses of the antibodies.

Claims (19)

1. An antibody, wherein the heavy chain variable region of the antibody has the amino acid sequence as set forth by SEQ ID NO: 3, and the light chain of the antibody has the amino acid sequence as set forth by SEQ ID NO: 2.

2. The antibody according to claim 1 , wherein the antibody comprises a heavy chain and the light chain, and the heavy chain comprises the heavy chain variable region and a heavy chain constant region.

3. The antibody according to claim 2 , wherein the heavy chain constant region comprises an amino acid sequence as set forth by SEQ ID NO: 11.

4. An inhibitor for inhibiting signal transduction pathway of the epidermal growth factor receptor or a tumor cell invasion, wherein the active ingredient of the inhibitor is the antibody of claim 1 .

5. The inhibitor according to claim 4 , wherein the tumor is a colon cancer.

6. The inhibitor according to claim 5 , wherein the tumor cell is a SW480 cell.

7. A drug for treating a tumor, wherein the active ingredient of the drug is the antibody of claim 1 .

8. The drug according claim 7 , wherein the tumor is a colon cancer.

9. The drug according claim 8 , wherein the tumor cell is a SW480 cell.

10. A method for treating a tumor comprising administering a therapeutically effective amount of preparing a drug comprising the antibody of claim 1 .

11. The method according to claim 10 , wherein the tumor is a colon cancer.

12. The method according to claim 11 , wherein the tumor cell is a SW480 cell.

13. A method of inhibiting signal transduction pathway of epidermal growth factor receptor comprising administering a therapeutically effective amount of the antibody of claim 1 to an individual in need thereof.

14. A method of inhibiting a tumor cell invasion comprising administering a therapeutically effective amount of the antibody of claim 1 to an individual in need thereof.

15. The method according to claim 14 , wherein the tumor is a colon cancer.

16. A method of treating a tumor comprising administering a therapeutically effective amount of the antibody of claim 1 to an individual in need thereof.

17. The method according to claim 16 , wherein the tumor is a colon cancer.

18. The method according to claim 15 , wherein the tumor cell is a SW480 cell.

19. The method according to claim 17 , wherein the tumor cell is a SW480 cell.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2013
From: GUANGZHOU RECOMGEN BIOTECH CO., LTD.
To: GUANGZHOU YUNYUAN BIOTECH CO., LTD.
Reel/Frame 030475/0142 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2012
From: INSTITUTE OF BIOTECHNOLOGY CHINESE PLA ACADEMY OF MILITARY MEDICAL SCIENCES
To: GUANGZHOU RECOMGEN BIOTECH CO., LTD.
Reel/Frame 028862/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2012
From: WEAVER, DAVID; RYNKIEWICZ, MICHAEL; CAO, CHENG; JIN, YANWEN
To: INSTITUTE OF BIOTECHNOLOGY CHINESE PLA ACADEMY OF MILITARY MEDICAL SCIENCES
Reel/Frame 028843/0780 →
Priority Claims (1)
CN 2009 1 0237803 · Nov 11, 2009 · national
Continuity (1)
Related Publication 20130022624A1 · Jan 24, 2013